|
ORF cDNA clones
|
CRISPR / TALEN
|
Lentivirus
|
AAV
|
TALE-TF
|
ORF knockin clones
|
|
Antibody
|
Proteins
|
miRNA target clones
|
qPCR primers
|
shRNA clones
|
miRNA products
|
Promoter clones
|
Validated All-in-One™ qPCR Primer for MAPT(NM_005910.5) Search again
Product ID:
HQP011022
(click here to view gene annotation page)
Powered by BiozSpecies:
Human
Symbol:
Alias:
DDPAC, FTDP-17, MAPTL, MSTD, MTBT1, MTBT2, PPND, PPP1R103, TAU, Tau-PHF6, tau-40
Gene Description:
microtubule associated protein tau
Target Gene Accession:
NM_005910.5(click here to view gene page)
Estimated Delivery:
Approximately 1-3 weeks, but may vary. Please email sales@genecopoeia.com or call 301-762-0888 to confirm ETA.
Important Note:
By default, qPCR primer pairs are designed to measure the expression level of the splice variant (accession number) you selected for this gene WITHOUT consideration of other possible variants of this gene. If this gene has multiple variants, and you would like to measure the expression levels of one particular variant, multiple variants, or all variants, please contact us for a custom service project at inquiry@genecopoeia.com.
Validated result:
|
|
| A | B |
|
Each All-in-One™ qPCR Primer is experimentally validated to yield a single dissociation curve peak and to generate a single amplification of the correct size for the targeted gene. A cDNA Pool, containing reverse transcript products of 8 different human tissue total RNA(Liver, Testis,Muscle,Thyroid,Brain,Spleen,Stomach,Small Intestine)),was used as the qPCR validation template. qPCR was performed using 0.2 µM primer with 2XAll-in-One™ qPCR Mix (Catalog#: QP001,QP002,QP004,QP005). Reactions were incubated for 10min. at 95°C, followed by 40 cycles of 95°C for 10 sec.; 60°C, 20 sec. and 72°C, 15sec. using Bio-Rad iQ5™ Instrument. At the end of the last cycle, temperature was increased from 72 to 95°C to produce a melting curve. Panel A: Validated Result for Amplification Curve; Panel B: Validated Result for Melting Curve. |
|
Summary
This gene encodes the microtubule-associated protein tau (MAPT) whose transcript undergoes complex, regulated alternative splicing, giving rise to several mRNA species. MAPT transcripts are differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. MAPT gene mutations have been associated with several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy.
Gene References into function
- Associated with etilogical mechanism of Alzheimer's disease.
- a biomarker for Alzheimer disease
- Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease.
- The glycosylation of tau is an early abnormality that can facilitate the subsequent abnormal hyperphosphorylation of tau in Alzheimer's disease brain.
- This suggests that usually FTDP-17 and PSP, including the rare familial form of PSP, are likely to be separate conditions and that usually PSP and typical PSP-like syndromes are not due to mutations in tau.
- The tau H1 haplotype is associated with increased risk of Parkinson disease in a Norwegian population.
- Modelling Alzheimer-specific abnormal Tau phosphorylation independently of GSK3beta and PKA kinase activities.
- Tau is essential to beta -amyloid-induced neurotoxicity
- additional regulatory sequences rugulating tau exon 10 splicing
- Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred.
- These results provide strong evidence suggesting that MAP2c and tau stabilize microtubules by binding along individual protofilaments, possibly by bridging the tubulin interfaces.
- Pick's disease is characterized by accumulation of Pick bodies in the hippocampus and cortex, and by the presence of microtubule-binding repeat tau pathology in gray and white matter, distinguishing this tauopathy from other neurodegenerative disorders.
- Results suggest that binding of tau to DNA occurs in an aggregation-dependent, and a phosphorylation-independent, manner.
- In aging and sporadic Alzheimer's disease, severe tau pathology (stage 7 to stage 10) correlates well with a huge and widespread Abeta burden.
- new insights into the conformation of tau in the soluble state and after incorporation into paired helical filaments
- no evidence seen for association of tau gene polymorphism with transmissible spongiform encephalopathies
- biochemical analysis in argyrophilic grain disease, Alzheimer's disease, and Pick's disease
- Expression of mutant human tau isoform in transgenic mice resulted in the development of congophilic hyperphosphorylated tau inclusions in forebrain neurons.
- phosphorylation by cdk5 and GSK-3beta
- two phosphorylation sites (serines 262 and 356) were identified in the tubulin binding sites. When tau was phosphorylated by CaM kinase II, the binding of tau to taxol-stabilized microtubules was remarkably impaired.
- REVIEW: tau dysfunction can lead to neurodegeneration and the development of clinical symptoms
- This is a possible candidate gene in frontal lobe dementia.
- The phenotype of pallidopontonigral degeneration (PPND) resulting from N279K mutation of tau includes dysfunction of the autonomic nervous system, correlating with the duration of illness and clinical and functional severity of parkinsonism.
- Repeat motifs of this protein bind to the insides of microtubules in the absence of taxol
- Tau isoforms are O-GlcNAc modified (a marker of healthy brain Tau) and a balance occurs between phosphorylation, glycosylation and nuclear localization
- can prevent DNA from thermal denaturation, improve renaturation and protect DNA from damage induced by free radicals
- The interaction of the amino terminus of tau with its microtubule-binding repeat regions, creating a conformation similar to that recognized by the monoclonal antibody Alz50, is very likely a propolymerization state of the tau molecule.
- Significant overrepresentation of the tau H1/H1 genotype, also found in progressive supranuclear palsy and corticobasal degeneration, was found in the primary progresssive aphasia group.
- Paired helical filament-tau inhibits proteasome activity in Alzheimer disease brain
- results implicate the human tau gene as a target gene for the alternative splicing regulator Tra2 beta protein, suggesting that Tra2 beta may play a role in aberrant tau exon 10 alternative splicing
- This protein binds to DNA but not single-stranded DNA.
- A positive association between the H1 haplotype and frontotemporal dementia was found, consistent with the hypothesis that the tau gene, or nearby gene on the H1 haplotype, is a risk factor for frontotemporal dementia
- results suggest that interactions between alpha-synuclein and tau can promote their fibrillization and drive the formation of pathological inclusions in human neurodegenerative diseases
- Sequence variations in intronic or regulatory regions of tau may have previously unrecognized consequences leading to tau dysfunction and neurodegeneration.
- cdk5 can initiate a major impact on tau pathology progression that probably involves several kinases.
- Frontotemporal dementia and parkinsonism with the P301S tau gene mutation in a Jewish family.
- In this study the presence of tau and 14-3-3 proteins in GCIs of 21 patients with MSA was investigated.
- MAPT mutations are not connected with most of the frontotemporal dementia cases in the Polish population.
- The authors describe a case of clinically diagnosed young onset progressive supranuclear palsy (PSP) with symptom onset at 40 years of age, no family history and tau exon 10 +16 mutation (MAPT, IVS10, C-U, +16)
- native filaments from brain and filaments assembled in vitro from expressed tau protein have a clear cross-beta structure
- expressed normal and FTDP-17 mutant human tau (mutations P301L and V337M) in Caenorhabditis elegans to model tauopathy disorders
- L266V is a pathogenic tau mutation that is associated with Pick-like pathology.
- tau is proteolyzed by multiple caspases at a highly conserved aspartate residue (Asp421) in its C terminus in vitro in neurons in Alzheimer's disease
- Nitrative injury is directly linked to the formation of filamentous tau inclusions.
- The presence of filamentous tau protein in the frontal cortex of these patients suggests a possible link between tau and the genetic defect present on chromosome 3 and associated with FTD-3.
- CSF-tau was a useful biological marker to discriminate Alzheimer's disease from normal aging, neurological and psychiatric disorders.
- A novel mechanism of apoptotic cell death is suggested in mutant TauP301L (but not in wild-type)-expressing cells that involves survivin-mediated activation of cell cycle checkpoint.
- tau binds to Hsc70, and its phosphorylation is a recognition requirement for the addition of ubiquitin
- novel, physiological role of the N-terminal domain of tau, but also underlay that its possible proteolytic truncation mediated by apoptotic proteases may generate a highly toxic fragment that could contribute to neuronal death
- Overexpressing the longest human tau isoform in rat astrocytes resulted in increases in tubulin biosynthesis and the accumulation of acetylated, tyrosinated, alpha- and beta-tubulin
- results indicate that in an appropriate cellular context R406W tau is hyperphosphorylated, which leads to decreased microtubule binding
- Tau, modified after ischemia, undergoes a reversible conformational change on Triton-X exposure. Because conformation at Ser101 of bovine tau is crucial for its affinity to tau2, this Ser-like conformation mimicked by its human counterpart.
- Casein kinase 1 delta phosphorylates tau at sites that modulate tau/microtubule binding
- Structure of tau from Alzheimer brain paired helical filaments is based on beta structure embedded in an environment of unstructured protein with no measurable indication of alpha-helical structure, thus it can be classifed as "amyloid" in a broad sense.
- It is proposed that the progression from amorphous aggregation of tau through intermediate formation and fibrillization may underlie the activity of other inducers such as hyperphosphorylation and may be operative in vivo.
- tau binds to heat shock protein 27, leading to decreased concentration of hyperphosphorylated tau and enhanced cell survival
- NMR spectroscopy and fluorescence mapping demonstrate that the epitope centered around the phospho-Thr212-Pro213 motif of Tau is a newly recognized Pin1 prolyl cis/trans-isomerase interaction site.
- an increase in expression of the MAPT gene is a susceptibility factor in idiopathic PD.
- This study found exon 9 to 13 of the tau gene have deletation of the conserved asparagin 296.
- Overexpression of human tau in Drosophila larvae disrupts axonal transport causing vesicle aggregation and this is associated with loss of locomotor function.
- Tyrosine phosphorylated tau is distributed in Alzheimer disease brain differently from other phosphorylated tau. Evidence of differentially phosphorylated tau within degenerating neurons was found supporting a role for fyn in neurodegeneration
- Increase of soluble Abeta42 and Abeta40 in FTDP-17, compared to normal and DLDH brains, both of which had comparable levels of Abeta species.Immunoreactivity of the intracellular Abeta42 was increased in cortical neurons of subjects with FTDP-17.
- we reconstituted naturally occurring exon 10 FTDP mutants and classified their effects on its splicing. We also carried out a survey of the influence of splicing regulators on Tau exon 10 inclusion and tentatively identified the site of action for severa
- Both 3- and 4-repeat tau isoforms suppressed microtubule dynamics, though to different extents.
- Expression of one particular tau isoform which contain exon 6, significantly inhibits neurite elongation in neuroblastoma cells .
- Evidence is provided for the first time that olfactory dysfunction is present in a transgenic mouse model of neurodegenerative tauopathy, including the filamentous tau tangles seen in Alzheimer's disease.
- In cells transfected with human tau, mitochondrial clustering was found in cells in which tau was unphosphorylated
- Both in multiple sclerosis and other inflammatory neurological diseases, tau protein levels in the cerebrospinal fluid (csf) are significantly higher than in csf samples from non-inflammatory neurological diseases.
- reversible binding occurs between tau and the surface of preassembled microtubules, whereas irreversible binding results when tau is coassembled with tubulin into a tau-microtubule copolymer
- In a case-control study a novel polymorphism in the tau gene (IVS11+ 90G-->A) shows significant association between possession of the A allele of tau and male Japanese Alzheimer's disease with early-onset.
- We show that the entire, fully extended H1 haplotype is associated with progressive supranuclear palsy, which implicates several other genes in addition to MAPT, as candidate pathogenic loci
- Tau phosphorylation is induced in vitro by down-regulation of WW domain-containing oxidoreductase
- Human mutant R406W tau transgenic mice developed an age-dependent accumulation of insoluble filamentous tau aggregates in neuronal perikarya of the cerebral cortex, hippocampus, cerebellum, and spinal cord
- Frontotemporal lobar degeneration can result from mutations in tau gene on chromosome 17. Brains with tau mutations accumulate insoluble tau within neurons and glia. Two new tau mutations may cause disease in absence of tau accumulation. Review.
- Hereditary frontotemporal dementia and parkinsonism linked to chromosome 17 caused by mutations in the tau gene shows a wide range in age at onset, several distinct clinical presentations, and a spectrum of tau pathology. Review.
- Staining for tau was negative in 5 of the frontal-lobe degeneration cases and faintly positive in 1, but positive in all Alzheimer's disease cases.
- we generated a series of constructs with intron deletions from full length tau exons 9-11. A minimum distance requirement between exon 10 and 11 for correct splicing was noted. SRp20 facilitates exon10 exclusion and FTDP-17 mutant exon 10 skipping
- A novel Tau isoform localizes differently from canonical Tau in SH-SY5Y cells which stably overexpress it. In both normal and Alzheimer's hippocampus it is in dentate gyrus granular cells and CA1/CA3 pyramidal cells, not with Tau but partly with MAP2
- We show that c-Jun N-terminal kinases JNK1 JNK2 and JNK3 phosphorylate tau at many serine/threonine-prolines; these findings extend the number of candidate protein kinases for tau hyperphosphorylation in Alzheimer's disease and neurodegenerative disorder
- filament growth wherein the existing filament serves as a template for the incoming, unfolded tau molecule, resulting in a new structured layer with maximized hydrogen-bonded contact surface and side-chain stacking.
- Results reveal a mechanism of regulation of tau phosphorylation and suggest that abnormal hyperphosphorylation of tau could result from decreased tau O-GlcNAcylation, which may be induced by deficient brain glucose uptake/metabolism.
- Strong genetic evidence for the involvement of tau gene variability in the pathogenesis of progressive supranuclear palsy (PSP) has been demonstrated in several Caucasian populations and is discussed in this review.
- in primary cultures, Akt selectively phosphorylates tau at S214 rather than T212 so tau S214 may participate in Akt-mediated anti-apoptotic signaling.
- As Alzheimer tablges evolve, the extreme N terminus of tau is lost & a C-terminal caspase-truncated epitope lacking AA 422-441 appears. Caspase-6 cleaved the N terminus of tau in vitro at D13, a semicanonical, undescribed caspase cleavage site in tau.
- Review. 34 different pathogenic MAPT mutations in 101 families have been described & their differing phenotypes characterized. In vitro & transgenic studies show their effect on tau function. Tau's role in dementia is discussed.
- mutations in this gene are not a frequent cause of the frontotemporal dementia phenotype in Canadian patients.
- beta-amyloid and tau-bearing skeletal myotubes show calcium dyshomeostasis
- Tau H1 contains an important susceptibility allele contributing to increased risk of neurodegeneration
- These results indicate that the patterns of the tau epitopes represented by this panel that reside in the pathological aggregates of PSP and CBD are similar to each other but distinct from that of AD.
- a mutant human tau protein causes induction of inflammatory mediators and microglial activation in the mouse model
- tau phosphorylation and PP2A activity are regulated by Galpha12
- Neuronal tau non-specifically functions in a chaperone-like manner towards the enzymes of carbohydrate metabolism, e.g., lactate dehydrogenase.
- possible role for thrombin in proteolysis of tau under physiological and/or pathological conditions in human brains
- tau is probably a physiological substrate of protein phosphatase 5 (PP5) and that the abnormal hyperphosphorylation of tau in Alzheimer disease might result in part from the decreased PP5 activity in the diseased brains
- Data are compatible with the notion that tau aggregates predispose neurons to develop secondary Lewy bodies.
- Our results support the notion that tau gene H1 haplotype may be an important risk factor of PD.
- The conformation of the tau protein was studied because of its importance in maintaining the shape of the axon.
- the initial structural moiety and its structural feature necessary for starting the tau paired helical filament formation of tau
- Results suggest that tau causes a conformational shift in microtubules resulting in altered dynamics.
- 4-hydroxy-2-nonenal modifications of tau promote and contribute to the generation of the major conformational properties defining neurofibrillary tangles
- was an increased risk of PD for persons with either SNCA 261/261 or MAPT H1/H1 genotypes as compared with persons with neither. The combined effect of the two genotypes was the same as for either of the genotypes alone (separate and equal).
- a mechanism through which site-specific posttranslational modifications can modulate filament accumulation at low free intracellular tau concentrations
- results demonstrate that glyceraldehyde-3-phosphate dehydrogenase, a glycolytic and microtubule binding protein, co-localized to neurofibrillary tangles and immunoprecipitated with paired helical filament-tau
- tau FTDP-mutation N279K is implicated in dementias.
- novel missense mutation in exon 12 of the tau gene, G335V, in a German family with frontotemporal dementia of early age at onset, in the third decade of life
- underlying variations in MAPT could contribute to disease pathogenesis by subtle effects on gene expression and/or splicing
- These results obtained in vitro and in vivo demonstrate that endogenous tau is not normally degraded by the proteasome.
- the aggregation of recombinant full-length four-repeat tau (htau40) was examined in vitro under near-physiological conditions using transmission electron microscopy and spectroscopy methods
- In Alzheimer's disease, phosphorylated tau protein, the major component of neurofibrillary tangles, is considered a central mediator of disease pathogenesis.
- abnormal nitration of tau contributes to the impaired biological activity of tau in binding to the microtubules, implying a novel mechanism responsible for the neurodegeneration seen in AD brain
- analysis of tau binding sites important for beta-structure and for binding to microtubules and polyanions
- In both primary hippocampal neurons and mice, the tau-induced Golgi apparatus (GA) fragmentation was not caused by apoptosis. Tau implicated in GA fragmentation. This occurs before formation of neurofibrillary tangles.
- analysis of phosphopeptides related to the human tau protein
- tau genotype does not influence the disease course, however, may predispose to a specific clinical sign in the early stage of FTDP-17 frontotemporal dementia Parkinsonism
- Familial frontotemporal dementia associated with the novel MAPT mutation T427M.
- This study indicates that post-translational events are likely to be the main factors controlling tau isoform composition in sporadic tauopathies and highlights the benefit of quantitative RT-PCR in the assessment of splicing abnormalities in tauopathies
- These data indicate that 14-3-3zeta may not be directly interacting with GSK3beta and tau in the brain, but may indirectly facilitate the interactions by binding to other proteins.
- The seventh residue of the second and third repeat fragments (R2 and R3 peptides) of the microtubule-binding domain (MBD)is very important for tau filamentous assembly.
- These data suggest that several species of tau are variably phosphorylated at a given time in a given region (and probably in a given cell), and that tau aggregates are composed of several phosphorylated truncated or cleaved tau molecules.
- Mutations do not affect the phosphorylatability of FTDP-17 tau by Cdk5 complexed with p35, p25, or p39
- The levels of t-tau and p-tau were higher in MS patients than in controls; however, increased levels were not related to the clinical activity of the disease.
- CaM kinase II is involved in the accumulation of tau in neuronal soma in Alzheimer's disease brain.
- The studied tau genotype may contribute to the multifactorial genetic background of ALS.
- Tyr-18 was the major site for Fyn phosphorylation, but Tyr-394 was the main residue for Abl. Phosphorylation of tau on Tyr-394 is a physiological event that is potentially part of a signal relay
- after the suppression of transgenic tau in mice with progressive age-related neurofibrillary tangles, memory function recovered
- Our results demonstrate that tau over-expression in vivo cause a synaptic dysfunction, which may be caused by a reduced complement of functional mitochondria.
- H2 haplotype is derived from Homo neanderthalensis and entered H. sapiens populations during the co-existence of these species in Europe from approx. 45000 to 18000 years ago. (review)
- This novel yeast model recapitulates hyperphosphorylation, conformation, and aggregation of protein tau and provides insight in molecular changes crucial in tauopathies.
- the Fyn-tau interaction has a role in neurodegeneration
- These findings challenge the idea that tau pathology in Alzheimer's disease is merely a downstream effect of amyloid production/deposition and suggest that reciprocal interactions between beta-amyloid and tau alterations may take place in vivo.
- Abeta but not tau is deregent-insoluble early in the pathogenesis of Alzheimer's disease
- A new mutation of the tau gene, G303V, in early-onset familial progressive supranuclear palsy.
- Our study indicates that the apoE epsilon4 carrier status should be considered when CSF P-tau(231P) is evaluated as biomarker candidate of AD in MCI subjects.
- The axonal transport of tau occurs via a mechanism utilising fast transport motors, including the kinesin family of proteins, and that alpha-synuclein transport in neurons may involve both kinesin and dynein motor proteins.
- These results suggest that R406W tau Tg mice exhibit changes in depression-related behavior involving serotonergic neurons and provide an animal model for investigating AD with depression.
- High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy.
- Accumulation of tau in transgenic mice expressing human tau exclusively in oligodendrocytes causes neurodegeneration by disrupting axonal transport
- Cu2+ plays an important role in the aggregation of R2 peptide (derived from the second repeat region of tau protein) and tau protein and that copper binding to R2 peptide may be another possible involvement in AD.
- Abeta(42)-mediated decrease in tau solubility depends on the interplay of distinct phospho-epitopes of tau and not only on phosphorylation of the S422 epitope
- Human protein tau inhibits DNA replication.
- the phenotype observed in affected individuals from P301S MAPT mutation families is heterogeneous and is broader than the phenotypes seen to date in affected family members carrying other MAPT mutations
- analysis of tau repeat domain in a model of tauopathy
- A Degeneration, Frontotemporal Lobar patient at-risk status for the +16 exon 10 splice mutation in the tau gene (microtubule associated protein tau, MAPT), which had given rise to progressive behavioural disturbances in two of his siblings.
- Familial autosomal dominant cortico-basal degeneration with the P301S mutation in the tau gene.
- Misregulation of alternative splicing of tau exon 10 seems to contribute to sporadic AD.
- In this work, we have found that in the presence of acetylsalicylic acid, at a concentration like that used for anti-inflammatory treatments, tau phosphorylation at serine 422 decreases.
- Our results demonstrate that the flow cytometry-based method is a convenient tool to analyze the effect of GSK-3beta inhibitors on Tau phosphorylation.
- Tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation in Alzheimer's disease
- Blocking the sites where amyloid-beta protein initially binds to tau might arrest the simultaneous formation of plaques and tangles in Alzheimer's disease
- Abeta and hyperphosphorylated tau formation in somatostatin cells are basically independent events Decreased somatostatin only partly goes together with cytoskeletal changes in somatostatin cells in nucleus tuberalis lateralis of Alzheimer's disease.
- SUMO1 is involved in a modification of tau and alpha-synuclein that may also have implications for their pathogenic roles in neurodegenerative diseases
- data show that chaperone induction results in the selective clearance of specific phospho-tau and conformationally altered tau species mediated by the proteasome
- PP2A-mediated dephosphorylation of HSP27 and tau correlated with PP2A-induced preservation of endothelial cell cytoskeleton
- C-terminal end of tau folds over into vicinity of microtubule-binding repeat domain, N-terminus remains outside FRET distance of repeat domain, yet both ends of molecule approach one another.
- These findings unravel a cellular mechanism linking tau toxicity to NMDAR activation and might be relevant to Alzheimer's disease and tauopathies where NMDAR-mediated toxicity is postulated to play a pivotal role.
- Shift in the ratio of three-repeat tau and four-repeat tau mRNAs in individual cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer's disease
- The role of JNK activation in the hyperphosphorylation of abnormal tau protein during mitosis is reported.
- In DMI Tau exon 6 is mis-regulated only in the brain tissue.
- Sequencing the MAPT gene in affected individuals revealed a change in intron 9. This finding supports earlier studies on the effect of a splice-accepting element in inclusion of exon 10 in the MAPT transcript.
- Nitration of Tyr18, Tyr29, Tyr197, & Tyr394, events known to stabilize pathological Alz-50 conformation inhibits ability of monomeric tau to promote tubulin assembly. Alz-50 conformation may be mechanism through which tau nitration modulates MT stability
- S422E tau is more resistant to proteolysis by caspase 3 than non-pseudophosphorylated tau. Tau phosphorylation at S422 may be a protective mechanism that inhibits cleavage in vivo.
- The composite Guam parkinsonism-dementia complex neuropathology profile of tau, alpha-synuclein and 8, 12-iso-iPF(2alpha)-VI isoprostane reported here more closely resembles that seen in other tauopathies including frontotemporal dementias (FTDs).
- Phosphorylation of serine and threonine residues in proline-rich sequences of tau protein induces a conformational change to a type II polyproline helix.
- Suppressing the transgene (tau)prevented further neuronal loss without removing or preventing additional accumulation of neurofibrillary pathology.
- Cerebrospinal fluid levels of tau are significantly increased in patients with multiple system atrophy predominated by parkinsonism.
- site-specific phosphorylation and caspase cleavage of tau differentially affect the ability of tau to bind and stabilize microtubules and facilitate tau self-association
- Microdeletions of this protein within the 17q21.31 segment should be considered as a possible cause of phenotypes resembling Angelman synrome.
- APP is transported on vesicles distinct from the secretase components and amyloid-beta is not generated in transit when transport is blocked by tau
- These findings suggest that the nonfibrillized P-tau is most likely the responsible entity for the disruption of microtubules in neurons in Alzheimer's disease (AD).
- Targeted expression of tau in hippocampal slices provides a novel model to analyze tau modification and spatiotemporal dynamics of tau-dependent neurodegeneration.
- biochemical analysis of neurofibrillary changes revealed that massive sarcosyl insoluble tau complexes consisted of human Alzheimer's tau
- A putative intronic splicing enhancer located in intron 10 of the tau gene is required for the splicing stimulatory activity of RBM4
- hyperphosphorylated-tau specific local phosphorylation patterns at Thr212/Ser214 and Thr231/Ser235 using monoclonal antibodies (mAb) generated against correspondingly modified peptides
- Studies demonstrate that the full morphological phenotype of IBM including beta-amyloid and tau protein deposits may also develop in children, and that congenital muscle defects may lead to abnormal protein aggregation in IBM-like inclusions.
- Hyperphosphorylation of tau may be an underlying point of pathological convergence for several neuropsychiatric disorders, and prevention of tau hyperphosphorylation may be an important therapeutic target. (REVIEW)
- Overexpression of mutant (P301L) human tau in CHIP-/- mice is insufficient to promote either argyrophilic or "pre-tangle" structures, despite marked phospho-tau accumulation throughout the brain.
- granular Tau aggregates have pathological roles in neuronal processes in tauopathies
- used tissue specific expression of wild type and mutant human tau transgenes to demonstrate differential phosphorylation and stability in a cell type-specific manner, which includes different neuronal types
- the age at onset showed significant correlation with the genotypes of Del-568TIns in PD samples when analyzed by Kendall rank correlation test. These results suggested that MAPT gene variants may modify the pathogenesis process of PD.
- This mouse model therefore displays the main features of tau pathology and several of the pathophysiological disturbances observed during neurofibrillary degeneration.
- Transgenic mice expressing the FTDP-17-associated mutation P301L of tau display intact spatial working memory but impairment in spatial reference memory at 6 and 11 months of age as well as a modest disinhibition of exploratory behavior at 6 mos of age.
- Residues 305 to 335 are essential for in vitro tau fibrillization.
- The progressive axonal pathology is most consistent with a dying-back process caused by abnormal accumulation of tau in upstream neurons, while vacuolar myelinopathy may be a secondary manifestation of neuroinflammation.
- A gene deletion of MAPT at chromosome 17q21.3 is associated with developmental delay and learning disability.
- Deletion of MAPT is associated with a common inversion polymorphism.
- Results provide the first structural insights into a folded state of tau, and support a role for lipid membranes in mediating tau function and tau pathology.
- We found no evidence that could support a major pathogenic role of STH and TAU haplotype in AD, FTD or PD.
- Data show that the addition of tau to cultured neuroblastoma cells provoked an increase in the levels of intracellular calcium, which is followed by cell death.
- Results reveal that expression of a truncated variant form of tau protein leads to the accumulation of reactive oxygen species and sensitizes rat cortical neurons to cell death induced by oxidative stress.
- tau turnover is dependent on degradation by the proteasome (inhibited by MG132) in HT22 neuronal cells.
- SRp54 interacts with a purine-rich element tau in exon 10 and antagonizes Tra2beta, an SR-domain-containing protein that enhances exon 10 inclusion.
- In this review microtubule-associated tau is one protein that has important functions in healthy neurons, but forms insoluble deposits in diseases now known collectively as tauopathies.
- recent work towards the unravelling of the functional basis of MAPT gene association with neurodegenrative disorders--review
- analysis of the role of microtubule binding repeats in tau aggregation and toxicity
- Ubiquitin-positive and tau-negative inclusions in clinical phenotypes were noted in cases of frontotemporal dementia (FTD), progressive non-fluent aphasia, type 2 histology with semantic dementia, and type 3 histology with FTD, and motor neurone disease.
- identify a region (positions 272-289) in the tau protein that, in the fibrillar state, either forms part of a core of parallel, in-register, beta-strands, or remains unfolded
- Glycogen synthase kinase 3 betais the missing link between the amyloid and tau-pathology in Alzheimer disease.
- Three-dimensional heteronuclear NMR experiments demonstrate that the interaction with heparin induces beta-strand structure in several regions of Tau that might act as nucleation sites for its aggregation.
- N-terminal tau fragments inhibit human Tau polymerization by interacting with a specific C-terminal sequence, thereby stabilizing a soluble conformation of tau.
- phosphorylation of tau at Thr231 and Ser262 by cdk5 plus GSK-3, which inhibits its normal biological activity, is regulated both by its amino terminal inserts and its physical state
- soluble Abeta and tau, but not soluble Abeta alone, have roles in cognitive decline in transgenic mice with plaques and tangle
- This study report the clinical, neuroimaging, cerebral spinal fluid biomarker, genetic, biochemical and postmortem neuropathological analyses of a case of familial FTD with a Leu266Val MAPT mutation.
- GSK-3beta-catalyzed tau phosphorylation sites promoted by prephosphorylation by PKA
- The common occurrence of intracellular accumulations of TDP-43 supports the hypothesis that these disorders represent a clinicopathological entity of a single disease, and suggests that they can be newly classified as a proteinopathy of TDP-43.
- Data may explain the increased susceptibility of H1 carriers to neurodegeneration and suggest a potential mechanism between MAPT genetic variability and the pathogenesis of neurodegenerative disease.
- These results suggest that a seminal cell biological event in Alzheimer's Disease pathogenesis is acute, tau-dependent loss of microtubule integrity caused by exposure of neurons to readily diffusible Abeta.
- Our result indicates that DYRK1A could be a key molecule bridging between beta-amyloid production and tau phosphorylation in AD.
- Beam walking tests revealed that tau transgenic rats developed progressive sensorimotor disturbances related to age; impaired reflex responses were another feature of behavioural phenotype in this novel transgenic rat.
- evidence of molecular interactions between prion protein (PrP) and tau protein highlights a potential role of tau in the biological function of PrP and the pathogenesis of TSEs
- haplotype increases both the expression of total MAPT transcript as well as specifically increasing the proportion of 4 microtubule binding repeat containing transcripts in Alzheimer disease
- While Lys-280 and Lys-281 play inhibitory roles in tau aggregation, Lys-311 is required for tau to assemble into fibrils.
- Data suggest that a probable cause variant may lie at or within close proximity to the rs242557 single nucleotide polymorphism as association with CSF tau levels seems to be primarily driven by rs242557 in a gene dosage-dependent manner.
- Two independent cis-acting sites presumably influence risk for Guam neuro-degenerative disorders by regulating MAPT expression.
- The novel Tau mutation G335S in patient with Frontotemporal Lobar Degeneration .
- Biochemical features of Alzheimer disease is modification by phosphorylation of the microtubule-associated protein TAU.
- The data presented here suggest that subhaplotypes of haplotype H1 may confer susceptibility to Parkinson's disease (PD), and that either allelic heterogeneity or different haplotype composition explain the divergent haplotype results.
- Our data suggest that the tagged SNPs forming the H1c haplotype at the MAPT locus do not have a causal role in the pathogenesis of late onset Alzheimer's disease
- Mutations in exons 1 and 10 of TAU were associated with progressive supranuclear palsy.(
- Inhibition of Hsp90 led to decreases in p-tau levels independent of heat shock factor 1 (HSF1) activation.
- analysis of the tau-microtubule interaction
- findings suggest that disruption of the microtubule network in presynaptic nerve terminals could constitute early events in the pathological process leading to synaptic dysfunction in tau V337M pathology
- The N-terminal region projects from the microtubule surface, and the lack of chemical shift variations when compared with free Tau proves that this region can regulate microtubular separation without adopting a stable conformation.
- The tau-4R isoform essentially contributes to hippocampal development by controlling proliferation and differentiation of neuronal precursors.
- In this model we suggest a possible role for tau phosphorylation, but not for tau aggregation, in the cognitive impairment found in the transgenic mouse.
- REVIEW: Microtubule-associated protein tau as a therapeutic target in neurodegenerative disease and their molecular rationales
- These results suggest that phosphorylation of tau plays a dual role in modulating the activity of proteasome.
- Transition between vastly different healthy and pathological forms of tau was studied.
- These findings do not support an association of MAPT with FTD but do not rule out its association with other tauopathies.
- There were dramatic changes in t-tau protein levels throughout the clinical course of Creutzfeldt-Jakob disease patients
- Levels of early-stage aggregated tau species (140 and 170 kDa), before the formation of neurofibrillary tangles, is associated with the development of functional deficits during the pathogenic progression of tauopathy in a transgenic mouse model.
- Review focuses on tau dysfunction for neurodegeneration and discusses mutations in the Tau gene in cases with frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).
- The epitope of anti-tau mAb Tau5 was mapped to the human tau sequence 218-225, which is not phosphorylated in vivo.
- Increasing P-tau levels during cognitive decline and conversion to dementia suggest that P-tau may be useful as a longitudinal marker of the neurodegenerative process.
- Strong evidence that the H1 clade, which contains MAPT and several other genes, is a risk factor for Parkinson's disease.
- the FTDP-17 tauV337M mutation has a role in impairment in impulse control that is exacerbated by age
- Fine mapping of the MAPT region has identified sub-clades of the MAPT H1 haplotype which are specifically associated with neurodegenerative disease
- Intermolecular disulfide crosslinking along with PHF6 hexapeptide facilitates tau oligomerization; this event is accompanied by cysteine-independent intermolecular bridging of microtubule-binding domain, leading to assembly of higher-order oligomers.
- phosphorylation sites in tau from Alzheimer brain show that casein kinase 1delta may have a role, together with glycogen synthase kinase-3beta, in the pathogenesis of Alzheimer disea
- GSK3beta facilitates the association of T4 and T4C3, and the presence of caspase-cleaved tau is necessary for the evolution of tau oligomers into Sarkosyl-insoluble inclusions even though it is not extensively phosphorylated
- In both cell culture and post-mortem brain tissue, we show that the protective MAPT H2 haplotype significantly expresses two-fold more 2N (exons 2+3+) MAPT transcripts than the disease-associated H1 haplotype.
- Our results are not consistent with a nucleation-elongation reaction but are consistent with an allosteric regulation model; the presence of small molecules induce a conformational change that decreases the thermodynamic barrier for polymerization.
- Role of MAPT H1 haplotypes in the etiology of Parkinson's disease may be ethnically dependent.
- The H1/H1 genotype carriers showed a significant increase in 4R/3R mRNA ratio, suggesting that this genotype could modulate the tau mRNA splicing.
- novel MAPT mutation (P301T) is associated with familial frontotemporal dementia.
- Tau and alpha-synuclein are involved in shared or converging pathways in pathogenesis of Parkinson's disease(PD). Tau inversion influences development of cognitive impairment and dementia in patients with idiopathic PD.
- Synthesis of phenylthiazolyl-hydrazide derivative (PTH)showed that it was active in inhibiting tau aggregation and in disassembling preformed aggregates. Analysis of the binding epitope shows strong interactions between the tau and the ligand.
- Our study does not support the theory that chromosomal rearrangements in the Tau region of chromosome 17 are a cause of FTLD.
- We demonstrated increased but largely variable 4R tau/3R tau mRNA ratios in FTLD and PSP cases, suggesting heterogeneous pathophysiological processes within these disorders.
- Our results demonstrate that dysregulation of combinatorial splicing might serve as a signature for aging-related diseases, and the polony assay could be widely adapted for the study of other tauopathies
- The levels of apoE in cerebrospinal fluid were also correlated to the levels of Tau and the possibility is discussed that the level of apoE in cerebrospinal fluid may be used as a marker of neurodegeneration.
- while the extended MAPT H1 and H2 haplotypes do not appear to confer risk for frontotemporal dementia development, the H2 haplotype appears to modify age at onset and functionally shows a more severe decline of glucose utilization in frontal brain areas
- This indicates that if the majority of tau is phosphorylated at S396/S404, in combination with increased GSK3beta activity, tau aggregation is favored.
- Despite the increased CSF concentrations of amyloid-beta, there were no signs of an Alzheimer disease-indicating tau pattern in CSF of Down syndrome patients, strengthening the theory of Abeta pathology preceding tau pathology in Alzheimer's.
- the N-terminal projection domain of tau binds to the C-terminus of the p150 subunit of the dynactin complex
- Data show that high t-Tau levels in CSF are found in pediatric patients with a brain tumor, patients with hydrocephalus and patients with a serious CNS infection.
- BAG-1 associates with Tau protein in an Hsc70-dependent manner.
- Thus, it is proposed that the negative charge present in taurine may be involved in the binding to tau protein, facilitating its assembly.
- An impaired control of glycogen synthase kinase-3beta activity by insulin receptor-mediated signalling plays a role in the pathogenesis of AD, facilitating tau protein phosphorylation and neurofibrillary tangle formation.
- Data demonstrate that aged (>20 months old) mice expressing wild-type human tau display impaired place learning and memory, even though they do not form neurofibrillary tangles or display neuronal loss.
- No patients had mutations of MAPT sporadic and familial PSP.
- The molecular interactions between PrP and tau protein highlight a potential role of tau in the biological function of PrP and the pathogenesis of transmissible spongiform encephalopathies.
- Tau phosphorylation at proline-rich region by dual-specificity tyrosine-phosphorylated and -regulated kinase 1A and at C-terminal tail region by glycogen synthase kinase-3beta affected its microtubule assembly activity and self-aggregation differently.
- multidisciplinary study of multiple system tauopathy with presenile dementia kindred; mutation +3 in intron 10 of Tau can give rise to a picture of FTD or atypical PSP; haplotype of wild-type allele may act as a modifier of disease presentation
- Syk is also a tau kinase, phosphorylating tau in vitro and in CHO cells when both proteins are expressed exogenously.
- Our study shows no evidence for an association between MAPT gene variations and sCJD, and some weak evidence for an association to vCJD
- report describes a tau S305S family where mutation carriers have frontotemporal dementia and parkinsonism; findings support previous studies demonstrating that the S305S mutation influences splicing of tau exon 10 & results in an overproduction of 4R tau
- MAPT and PGRN are responsible for the largest number of familial cases. Each of these genes differs by disease mechanism. Moreover mutations in both genes are associated with significant interfamilial and intrafamilial phenotypic variation.
- Data show that tau overexpression leads to impaired retrograde and anterograde organelle transport, while the microtubule skeleton appears intact.
- There is an increased neurogenesis during tau hyperphosphorylation and cell cycle events during abnormal tau phosphorylation and tau aggregation preceding neuronal death and neurodegeneration.
- To investigate associations of APOE, APOE promoter (G-219T), and tau protein exon 6 polymorphisms (47 and 53) and a history of self-reported concussion in college athletes
- Aggregated tau in neurons can be associated with caspase activation, but caspase activation is not sufficient to cause acute neuronal death in this transgenic mouse model.
- The observed effect of tau protein on neurons (in neuroblastomas and primary cultures of hippocampal and cortical neurons) is through M1 and M3 muscarinic receptors.
- Alzheimer disease-like clinical phenotype in a family with FTDP-17 caused by a MAPT R406W mutation.
- Patients with mutations may be affected by frontotemporal dmentia and parkinsonism linked to chromosome 17.
- This systematic study of the linkage-dependent contribution of each repeat peptide to the paired helical filament formation of tau microtubule-binding domain (MBD) is useful for understanding the essence of short and long filament formation of tau MBD.
- Our results identify a molecular mechanism by which proinflammatory stimuli affect tau pathology via the GSK-3beta signaling pathway in skeletal muscle.
- combined gene effects between 14-3-3 zeta (intron 4, rs 983583) polymorphism and tau (intron 9, rs 2471738) polymorphism might be responsible for susceptibility to Alzheimer disease
- FTDP-17T is associated with symmetric frontotemporal atrophy and FTDP-17U with an asymmetric degenerative process in parkinsonism and frontotemporal dementia.
- Data provide the first evidence that 17beta-estradiol can inhibit PKA overactivation and PKA-induced tau hyperphosphorylation, implying a preventive role of 17beta-estradiol in AD-like tau pathology.
- Results describe the detailed characterization of tau in human cerebrospinal fluid.
- analysis of tau filament formation and the role of dimerization
- Expression of microtubule-associated protein tau, a major component of tangles, with an adeno-associated virus vector induces neuropathological sequelae in rats that are similar to those seen in human tauopathies.
- Senile systemic amyloidosis was associated with age, myocardial infarctions, the G/G (Val/Val) genotype of the exon 24 polymorphism in the alpha2-macroglobulin (alpha2M), and the H2 haplotype of the tau gene
- These results indicate the existence of a correlation between impairment of cerebral metabolism, estimated through FDG-PET, and CSF Tau protein levels.
- Mutations in the gene encoding the microtubule-associated protein tau (MAPT; OMIM +157140) on chromosome 17 have been found in many kindreds with familial FTDP.
- study found that the level of the catalytic subunit of PP2A(PP2Ac) was dramatically decreased in adult Down syndrome brain, and this decrease correlated negatively with tau leveland phosphorylation at several abnormal hyperphosphorylation sites
- These results indicate that tau is not randomly proteolyzed at different domains, and that proteolysis occurs sequentially from the C-terminus to inner regions of tau in AD progression.
- Taken together, the in vitro models and findings in AD suggest that in the presence of ubiquinone, Hirano bodies may result from the interaction of actin and other proteins, including tau.
- study describes the transient elevation of total tau levels in CSF of patients with Wernicke's encephalopathy, as well as the absence of elevated total tau in alcohol withdrawal delirium
- The ratio of CSF tau/A beta(42) is a sensitive and specific biomarker at discriminating frontotemporal lobar degeneration from Alzheimer disease in patients with known pathology.
- relative resistance to phosphatases might be a common feature of Cdk5 substrates and could contribute to the hyperphosphorylation of CRMP2 and Tau observed in Alzheimer disease
- Abeta and tau pathology are consistent with a model in which both synaptic loss and dysfunction are linked to a synaptic amyloid cascade within the synaptic compartment.
- Both animal and cell models, which were regulated under the natural tau promoter (of rat origin), provide authentic and reliable models for tauopathy, and offer valuable tools for understanding the molecular events underlying tauopathies including AD.
- The data are incompatible with tau acting as a monomer; rather, they indicate that two tau molecules associate in an antiparallel configuration held together by an electrostatic "zipper" of complementary salt bridges.
- Two hsc70 binding sites on tau are identified, as well as hydrophobic amino acids crucial for hsc70 binding.
- This study supports a role for MAPT in the pathogenesis of familial and idiopathic Parkinson disease (PD).
- A caspase-cleaved NH2-terminal tau fragment of 20-22 kDa, consistent with the size of the N-terminal 26-230 amino-acid neurotoxic fragment of tau, is generated in vitro in differentiated human SH-SY5Y cells.
- This endophenotype-based approach provides evidence for a gene (MAPT SNPs)-physiological environment (Abeta deposition) interaction that places changes in cerebrospinal fluid tau after Abeta deposition.
- VQIINK (280) and VQIVYK (311) are the major, if not sole, critical regions that directly mediate intermolecular contact between tau molecules during the early phases of Tau aggregation.
- parkin may counteract the alteration of tau metabolism in certain neurodegenerative diseases with tau cytopathy and parkinsonism
- Collectively, these findings suggest that Tau nitration at Tyr 18 may be linked to astrocyte activation, an early event associated with amyloid plaque formation.
- Findings argue for a role of tau in chromosome stability by means of its interaction with both microtubules and chromatin.
- Increased demethylation of PP2A mediated by Abeta overproduction or estrogen deficiency may contribute to the reduced PP2A activity observed in the AD brain, resulting in the compromised dephosphorylation of abnormally hyperphosphorylated tau.
- although PSEN1 mutations are the most frequent cause, the MAPT R406W mutation is an important cause of early-onset familial dementia clinically diagnosed as Alzheimer's disease in Japanese
- We conclude that the phosphorylation of tau by GSK-3beta either prior to or following polymerization promotes polymer/polymer interactions that result in stable clusters of tau filaments.
- using electrophoretic mobility shifting assay (EMSA) in the presence of DNA with different chain-lengths, we observed that tau protein favored binding to a 13 bp or a longer polynucleotide.
- These findings establish HDAC6 as a tau-interacting protein and as a potential modulator of tau phosphorylation and accumulation.
- mature, parkin null, over-expressing human mutated tau (PK(-/-)/Tau(VLW)) mice have altered behaviour and dopamine neurotransmission, tau pathology in brain and amyloid deposition in brain and peripheral organs
- review of modifications, phosphorylation and a specific form of glycosylation, O-linked -N-acetylglucosaminylation by O-GlcNAc, relevant to pathological tau phosphorylation
- Imbalance of 3R- and 4R-tau in DS brain by Dyrk1A-induced dysregulation of alternative splicing factor-mediated alternative splicing of tau exon 10 represents a novel mechanism of neurofibrillary degeneration
- These results suggest for the first time that variation of alpha-synuclein modulates neurofibrillary tau pathology and support the recent observations of an interaction of alpha-synuclein and tau in neurodegeneration.
- Results suggest that differential regulation of phosphorylation is important for neurofibrillary tangle formation in neurodegenerative diseases with tau pathology.
- This work is focused on the fourth microtubule-binding repeat (R4) of tau, which has an O-GlcNAcylation site-Ser356.
- simultaneous presence of human mutated Tau(VLW) and plaque-amyloid (and/or APP(SW)) potentiates and anticipates tau phosphorylation at the 12E8 epitope, intensifying pyramidal neuron immunostaining and tau filament formation in this alzheimer's model
- Expression levels of misfolded truncated tau determine life span in transgenic rat model of tauopathy without causing neuronal loss or correlating with terminal neurofibrillary tangle load.
- Residue K280 can adopt a loop/turn conformation in WT MTBR2 and that deletion of this residue, which can adopt nonextended states, leads to an increase in locally extended conformations near the C-terminus of PHF6*, aggregation-initiating sequence.
- Haplotype frequencies vary between those developing Alzheimer's disease in Down syndrome before 45 and those developing dementia after this age
- According to circular dichroism and NMR spectroscopy, Tau remains largely disordered upon binding to Cu(II), although a limited amount of aggregation is induced
- Whilst dementia severity is closely related to impaired cerebral glucose metabolism, CSF t-tau is less closely related and appears to be less well suited for assessment of disease progression.
- MAPT missense mutations can directly promote tau filament formation at different stages of the aggregation pathway.
- Data show that total serum bilirubin and mean serum Tau levels of infants who manifest auditory neuropathy, neurologic abnormalities, or EEG abnormalities are significantly higher than in infants without these abnormalities.
- Data show that the pathological deposits with antibodies against tau has involved in the neuropathogenesis of the amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam.
- We found differences between mouse and human tau in the regulation of exon 10 inclusion. Despite these differences, the isoform splicing pattern seen in normal human brain is replicated in our mouse models.
- Phosphorylation and microtubule binding plays a crucial role in the regulation of tau toxicity when misexpressed.
- FTDP-17 mutations in Tau alter the regulation of microtubule dynamics and demonstrate an "alternative core" model for normal and pathological Tau action
- Truncated tau production, which selectively affects brainstem neuron susceptibility, can be considered a specific marker for PSP. Tau form ratio was the lowest in progressive supranuclear palsy with no overlap with any other neurodegenerative illness.
- H/I resulted in a significant increase in tau fragments generated by caspase activation and a marked decrease in tau phosphorylation at residue T231 in cortex of wild-type but not transgenic mice.
- Considering pathologic abnormalities of these tauopathies and involvement of tau mutations seen in familial forms, MAPT gene represents most likely cause driving association.
- rs1880753 marker located 160 kb and 50 kb upstream of MAPT and CRHR1 genes respectively showed consistent association with disease risk and an earlier age at onset, suggesting that it could act as cis modifying factor of MAPT gene expression
- the combination of PARK2 gene deletion with hTauVLW over-expression in mice produces abnormal hyperphosphorylated tau aggregates, similar to those observed in the brain of patients diagnosed with certain tauopathies
- Data show that abnormal splicing with inclusion of exon 10 into tau mRNA has been observed in progressive supranuclear palsy and Alzheimer's disease patients.
- We conclude that although pathogenic MAPT mutations are rare in Northern Finland, the MAPT H2 allele may be associated with increased risks of FTLD and eoAD in the Finnish population.
- The role of PP2A in the phosphorylation of P301L mutant human tau and in neurofibrillary tangle pathology in vivo was determined.
- We found that inversion of the MAPT region is similarly polymorphic in other great ape species, and we present evidence that the inversions occurred independently in chimpanzees and humans
- In subjects who have mutations of MAPT, patterns of atrophy seen on head magnetic resonance imaging (MRI) show greater gray matter loss, compared to head MRI of subjects with mutations in progranulin (PGRN).